Jiangbo Pharmaceuticals, Inc. (Formerly known as Genesis Pharmaceuticals Enterprises, Inc.) Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010

LAIYANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., , a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:00 a.m. Eastern Time on Wednesday, November 18, 2009 to discuss financial results for its first quarter of fiscal year 2010.

Conference Call

Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO, will host the conference call.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 688 0796. International callers can dial (617) 614 4070. The conference passcode is 616 816 13.

If you are unable to participate in the call at that time, a replay of the conference call will be available from Wednesday, November 18, 2009 at 11:00 a.m. Eastern Time for 14 days. To access the replay, please call (888) 286 8010. International callers can dial (617) 801 6888. The conference replay passcode is 464 133 98.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, and electuary (sticky syrup) form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

CONTACT: Ms. Elsa Sung, CFO of Jiangbo Pharmaceuticals, Inc.,
+1-954-727-8435, elsasung@jiangbo.com; Investor Relations Contact: Crocker
Coulson, President of CCG Investor Relations, crocker.coulson@ccgir.com,
+1-646-213-1915 (NY office)

Web site: http://www.jiangbopharma.com//
http://www.ccgirasia.com/

Back to news